UCB acquires Lectus Therapeutics’ key pharmaceutical assets
Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus’s proprietary LEPTICS® technology for a number of further ion channel targets.
The drug discovery and development programmes acquired by UCB centre on the use of Lectus’s proprietary LEPTICS® technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.